Andrew Han covers breaking news for GenomeWeb. He tracks companies in the molecular biology research and diagnostic markets.
The Virginia-based firm's genetic genealogy service for forensics played a central role in a recent arrest in a 30-year-old double homicide case.
There has been a proliferation of firms aiming to apply blockchain technology to genomics. While challenges remain, it may just provide the security needed for data sharing.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
By combining in vivo and in vitro proximity ligation technologies, highly accurate and contiguous genomes can help accelerate more traditional, genetic-marker based crop breeding.
Dubbed "Sherlock," the new technology has demonstrated potential in detecting viruses and bacteria as well as human SNPs and mutations in cell-free DNA.
Reinstating the CRISPR patent interference with the Broad Institute would allow UC to argue that Jennifer Doudna and Emmanuelle Charpentier invented it first.
The Harvard spinout is commercializing inDrop single-cell sequencing technology developed by Allon Klein.
The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.
Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.
The firm envisions applying its new PlexSet technology to the upper end of multiplex gene expression analysis as well as CRISPR validation applications.
The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.
A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.
The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."
In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.